APTO News and Press, Aptose Biosciences Inc. From 11/01/22

─ Tuspetinib (HM43239) Dose Escalation and Exploration Phase 1/2 Trial in r/r AML Complete; Continued Superior Safety Profile and Clinical Responses Including Complete Remissions as Single Agent Across Three Dose Levels ─ ─ Recruitment Open for Tuspetinib Dose...

SAN DIEGO and TORONTO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter en...

SAN DIEGO and TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic m...

SAN DIEGO and TORONTO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malign...

– Initial modeling predicts up to 18-fold improvement in plasma steady-state exposure – – Supports exploration of continuous dosing of G3 formulation – – Lead clinical compound HM43239 continues to progress on schedule – ...

SAN DIEGO and TORONTO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic ma...

Aptose Biosciences Inc. (APTO) Q2 2022 Earnings Conference Call August 02, 2022, 05:00 PM ET Company Participants Susan Pietropaolo - Managing Director William Rice - Chairman, President and CEO Fletcher Payne - SVP and Chief Financial Officer Rafael Bejar - ...

Aptose Biosciences press release ( NASDAQ: APTO ): Q2 GAAP EPS of -$0.11 (vs. -$0.15 Y/Y) beats by $0.02 . Total cash and cash equivalents and investments as of June 30, 2022 were $62.4 million. For further details see: Aptose Biosciences GAAP EPS of -$0.11 b...

─ HM43239 Preliminary Response Rate of 43% Among R/R AML Patients with FLT3 Mutations Who Failed Prior Therapy with FLT3 inhibitors ─ ─ HM43239 Complete Remissions and Safety Across Three Dose Levels and Multiple Genotypic Subpopulations ─ ...

Aptose Biosciences ( NASDAQ: APTO ) is scheduled to announce Q2 earnings results on Monday, August 1st, after market close. The consensus EPS Estimate is -$0.13 and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 6 upward revisio...